• Patent Title: CARGO MOLECULE TRANSDUCTION DOMAIN RMAD1, VARIANT THEREOF, RECOMBINANT CARGO MOLECULE, AND METHOD FOR TRANSDUCING CARGO MOLECULE USING SAME
  • Application No.: US18288824
    Application Date: 2022-05-03
  • Publication No.: US20240207162A1
    Publication Date: 2024-06-27
  • Inventor: Chanho PARKSeongmin CHO
  • Applicant: REMEDI CO., LTD.
  • Applicant Address: KR Incheon
  • Assignee: REMEDI CO., LTD.
  • Current Assignee: REMEDI CO., LTD.
  • Current Assignee Address: KR Incheon
  • Priority: KR 20210062397 2021.05.14 KR 20220053247 2022.04.29
  • International Application: PCT/KR2022/006340 2022.05.03
  • Date entered country: 2023-10-30
  • Main IPC: A61K8/64
  • IPC: A61K8/64 C07K7/06 C07K7/08 C12N15/87
CARGO MOLECULE TRANSDUCTION DOMAIN RMAD1, VARIANT THEREOF, RECOMBINANT CARGO MOLECULE, AND METHOD FOR TRANSDUCING CARGO MOLECULE USING SAME
Abstract:
The present invention relates to a human ADARB2-derived cell-penetrating peptide and a cargo-molecule delivery system using the same, and provides a method for delivering cargo molecules into a cell, the method comprising a step for bringing a cargo-molecule transduction domain including the human ADARB2-derived RMAD1 or a variant thereof and a recombinant cargo molecule fused with the cargo molecule transduction domain into contact with cells. The cargo molecule transduction domain of the present invention not only can introduce cargo molecules into cells at a higher efficiency than existing cell-penetrating peptides, but is a polypeptide sequence derived from human proteins, and thus also has no risk of causing immune response problems. Thus the cargo molecule transduction domain is useful for delivering various polymer materials into human cells.
Information query
Patent Agency Ranking
0/0